Preview

November 2020

As Covid-19 vaccine candidates make their way through the clinical trial process, we investigate what can be done to counter the growing number of antivaxxers that oppose a pharmaceutical intervention. Plus, we take a look at the rising number of gout diagnosis and what pharma is doing to tackle this surge.

Also, we examine innovative ways to treat chronic pain without painkillers, find out what is being done to fix a lack of equal representation of Black, Latinx and Native American people in Covid-19 drug trials, and learn about Genoskin’s unusual alternative to animal testing that uses human skin models collected after plastic surgery procedures.

Plus, we take a look at a new breast cancer ‘ecosystem’ that contains promising new therapeutic targets for the pharma industry, speak to Atomwise about the company’s drug discovery platform AtomNet, and explore the potential of quantum computing in life sciences.

EDITORIAL

Editor | Eloise McLennan

Group Editor | Susanne Hauner

Commissioning Editor| Daniel Garrun

Writers | Allie Nawrat, Chris Lo, Abi Millar, Chloe Kent, Peter Kohut
Magazine Designer | Marzia Del Gaone

Graphic Designers | Filipe Costa, Anett Arc, Ashley McPherson, Tyrrell Lowe, Noemi Balint, Petra Konyi-Kiss, Maria Gimenez, Martina Labaiova
Lead Designer | John Hammond 
Digital Publishing Director | Duncan West

Advertising

Sales Manager | Nimai Amin

+44 (0) 207 936 6453

Marketing

For media partnership enquiries please contact: Susanne Hauner

Pharma Technology focus is powered by h5mag

read past issues of pharma technology focus HERE

Copyright 2020 NRi Digital, a trading division of Verdict Media Ltd. Registered office John Carpenter House, John Carpenter Street, London, EC4Y 0AN, UK. Company registration number 03171601. All rights reserved. No part of this publication may be reproduced in any form or by any means, electronic, photocopying or otherwise, without prior permission of the publisher and copyright owner. While every effort has been made to ensure the accuracy of this publication, the publisher accepts no responsibility for errors or omissions. The products and services advertised are those of individual authors and are not necessarily endorsed by or connected with the publisher. The opinions expressed in the articles within this publication are those of individual authors and not necessarily those of the publisher.

Go to article: Home | Under the microscopeGo to article: In this issueGo to article: SHL Medical Company InsightGo to article: SHL MedicalGo to article: ContentsGo to article: MimotopesGo to article: NewsGo to article: VEGA AustraliaGo to article: Covid-19 executive briefing by GlobalDataGo to article: WipotecGo to article: Nasal spray vaccine for Covid-19Go to article: Datwyler Company Insight Go to article: DatwylerGo to article: Covid-19 clinical trials continue to rise in BrazilGo to article: BiogazelleGo to article: AstraZeneca’s Phase I / II Covid-19 vaccine trial Go to article: SwiftpakGo to article: MTPA resumes screening and enrolment for global Phase III clinical trial of MT-1Go to article: Biesterfeld Go to article: The pharma industry briefingGo to article: From antitoxins to Covid-19 drugs: charting the history of antibody drugsGo to article: Quality control: pharma manufacturing inspections explainedGo to article: Molnár-Institute Company InsightGo to article: Molnar-InstituteGo to article: Oxytocin: the therapeutic potential of the ‘love hormone’Go to article: AI-enabled risk detection in pharma manufacturingGo to article: Dr. Paul LohmannGo to article: Addressing the long-term effects of Covid-19Go to article: Eyes on the prize: the latest in retinitis pigmentosa gene therapiesGo to article: HOF Sonderanlagenbau Company Insight Go to article: HOF SonderanlagenbauGo to article: Breaking the taboo: disrupting the fertility sectorGo to article: Neutralising the gluten threat: are we on the cusp of a coeliac disease breakthrough? Go to article: Nolato Company Insight Go to article: NolatoGo to article: Pharmacovigilance case intake: why the hesitation to automate?Go to article: Deals in brief powered by GlobalDataGo to article: The key list powered by GlobalDataGo to article: Zenatek Go to article: Global markets and indices powered by GlobalDataGo to article: Macro-economic indicators (1 of 2) powered by GlobalDataGo to article: Macro-economic indicators (2 of 2) powered by GlobalDataGo to article: EventsGo to article: Next issue